Intervention

Glucose-dependent Insulinotropic Polypeptide (GIP)

ClinicalTrials.gov intervention label

Clinical trials5

Recruiting1

Common conditions8

Lead sponsors shown4

Clinical trials

5 shown

A Study Looking at How Weekly Injections of Two Hormones - GIP and Amylin - Affect Stomach-related Side Effects in People Who Are Overweight or ObeseNCT07411560 · 2026-02-09

Glucose-dependent INsulinotropic Polypeptide: Effect on Bone Remodelling and Cell Activity (GINEBRA)NCT06790225 · 2025-11-10

The Separate and Combined Glucagonotropic Effects of Glucose-dependent Insulinotropic Polypeptide and Alanine in Subjects With and Without Type 1 DiabetesNCT06881472 · 2025-01-01

Xenin-25: Novel Regulator of Insulin Secretion and Beta-cell FunctionNCT00949663 · 2009-10-01

Study of the Effects of Xenin-25 in Humans With and Without Type 2 Diabetes MellitusNCT00798915 · 2008-12-01

Common conditions

Bone Disease, Metabolic1 Diabetes1 Diabetes Mellitus, Type 21 Obese1 Obesity and Obesity-related Medical Conditions1 Overweight1 Type 1 Diabetes1 Type 2 Diabetes Mellitus1

Leading sponsors

Washington University School of Medicine2 Asger Lund, MD1 Esbjerg Hospital - University Hospital of Southern Denmark1 Novo Nordisk A/S1

Trial status mix

COMPLETED4

RECRUITING1

Phase mix

PHASE13

NA2

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.